NICE recommends Novartis’ wet AMD drug Beovu
Final appraisal determination recommends anti-VEGF treatment for NHS use
Read More
Tag: wet AMD
Janssen buys rights to Hemera’s eye disease gene therapy candidate
Therapy targets CD59 protein to preserve vision in geographical atrophy patients
Read More
Bayer wins EU approval for Eylea syringe
The syringe provides a new streamlined method to administer Eylea
Read More
MHRA clarifies position on off-label Avastin
Roche’s drug has been used for years to treat wet AMD, an indication for which it is not specifically licensed
Read More
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
Read More
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche’s Avastin off-label if they believe it is clinically appropriate and in the patient’s best interest.
Read More
Regeneron calls time on Eylea/nesvacumab combo
Regeneron says that a combination of Eylea and nesvacumab being co-developed with Bayer will not move into Phase III testing for two eye conditions following disappointing Phase II data.
Read More
Bayer and Bradford Teaching Hospitals NHS FT open eye unit
Bradford Teaching Hospitals NHS Foundation Trust and Bayer have opened a new Macula Centre to expand and improve access to services for patients with wet Age-related Macular Degeneration (wet AMD), a leading cause of vision loss in adults.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
